Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel
NASDAQ:FHTX

Foghorn Therapeutics Q1 2026 Earnings Report

Foghorn Therapeutics logo
$4.71 +0.07 (+1.51%)
As of 11:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Foghorn Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.28
Beat/Miss
N/A
One Year Ago EPS
N/A

Foghorn Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$7.94 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Foghorn Therapeutics Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

Foghorn Therapeutics Earnings Headlines

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Moderate Buy" from Brokerages
May 5 at 4:10 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30759321
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/FHTX/pressreleases/36602402/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting/
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.tc pixel
May 6 at 1:00 AM  |  Weiss Ratings (Ad)
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/21/3278403/0/en/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting.html
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 9, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting-1036006666
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/09/3270778/0/en/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting.html
See More Foghorn Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Foghorn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Foghorn Therapeutics and other key companies, straight to your email.

About Foghorn Therapeutics

Foghorn Therapeutics (NASDAQ:FHTX) is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations. In addition to FHD-286, Foghorn maintains a pipeline of preclinical programs aimed at other chromatin targets, with the goal of advancing multiple development candidates into the clinic over the coming years.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics was established with support from leading life-science investors. The company operates research and development activities in the United States and collaborates with academic and industry partners to accelerate the translation of its discoveries into potential therapeutic options for patients worldwide.

Under the leadership of President and Chief Executive Officer Robert Mulroy, PhD, Foghorn has built a multidisciplinary team with expertise in epigenetics, medicinal chemistry, structural biology and translational medicine. The company’s strategic vision emphasizes innovation in chromatin biology and a commitment to developing differentiated treatments for oncology.

View Foghorn Therapeutics Profile
Earnings Tools